Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official VSports app下载. Federal government websites often end in . gov or . mil. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely V体育官网. .

Clinical Trial
. 2002 Jun;50(6):857-60.
doi: 10.1136/gut.50.6.857.

"V体育2025版" A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis

R K S Phillips  1 , M H Wallace, P M Lynch, E Hawk, G B Gordon, B P Saunders, N Wakabayashi, Y Shen, S Zimmerman, L Godio, M Rodrigues-Bigas, L-K Su, J Sherman, G Kelloff, B Levin, G Steinbach; FAP Study Group
Affiliations
Clinical Trial

A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis

VSports注册入口 - R K S Phillips et al. Gut. 2002 Jun.

Abstract

Background: Non-selective cyclooxygenase (COX) inhibitors (non-steroidal anti-inflammatory drugs) inhibit large bowel carcinogenesis in patients with familial adenomatous polyposis (FAP) VSports手机版. Their role in the duodenum of these patients is less certain. The disease modifying activity of specific COX-2 inhibitors has not been explored in humans. .

Patients and methods: This was a randomised, double blind, placebo controlled study of celecoxib (100 mg twice daily (n=34) or 400 mg twice daily (n=32)) versus placebo (n=17), given orally twice daily for six months to patients with FAP. Efficacy was assessed qualitatively by blinded review of shuffled endoscopy videotapes comparing the extent of duodenal polyposis at entry and at six months and quantitatively by measurement of the percentage change in duodenal area covered by discrete and plaque-like adenomas from photographs of high and low density polyposis V体育安卓版. .

Results: Shuffled and blinded video review showed a statistically significant effect of 400 mg twice daily celecoxib compared with placebo treatment (p=0 V体育ios版. 033) with all five independent observers scoring a beneficial effect. Overall, patients taking celecoxib 400 mg twice daily showed a 14. 5% reduction in involved areas compared with a 1. 4% for placebo (p=0. 436). However, patients with clinically significant disease at baseline (greater than 5% covered by polyps) showed a 31% reduction in involved areas with celecoxib 400 mg twice daily compared with 8% on placebo (p=0. 049). .

Conclusions: A panel of five endoscopists found a significant reduction in duodenal polyposis after six months of treatment with celecoxib 400 mg twice daily VSports最新版本. COX-2 inhibition may help this otherwise untreatable condition. .

PubMed Disclaimer

Figures

Figure 1
Figure 1
Investigators' assessments of the full extent of duodenal polyposis at videotaped review. The assessment was assigned a score of 0 (no change), +1 (clinical improvement), or −1 (deterioration) following placebo or celecoxib 100 mg or 400 mg twice daily (BID). Values are mean (SEM). p=0.033, celecoxib 400 mg twice daily versus placebo (Wilcoxon rank sum test).
Figure 2
Figure 2
Individual reviewer (physicians (Phy) A to E) video assessment of the duodenum. The assessment was assigned a score of 0 (no change), +1 (clinical improvement), or −1 (deterioration) following placebo or celecoxib 100 mg or 400 mg twice daily. Mean scores are shown.
Figure 3
Figure 3
Percentage change in area of duodenal polyposis from baseline (mean (SEM)) following placebo or celecoxib 100 mg or 400 mg twice daily. *Two patients with no baseline disease excluded. †p=0.436 versus placebo (Wilcoxon rank sum).
Figure 4
Figure 4
Duodenal polyposis, as seen during endoscopy before (A) and after six months of treatment with celecoxib (B).
See this image and copyright information in PMC

References

    1. Bussey HJR. Familial polyposis coli: family studies, histopathology, differential diagnosis, and results of treatment. Baltimore: John Hopkins University Press, 1975.
    1. Spigelman AD, Talbot IC, Penna C, et al. Evidence for adenoma-carcinoma sequence in the duodenum of patients with familial adenomatous polyposis. The Leeds Castle Polyposis Group (Upper Gastrointestinal Committee). J Clin Pathol 1994;47:709–10. - V体育官网 - PMC - PubMed
    1. Kashiwagi H, Spigelman AD, Talbot IC, et al. Over expression of p53 in duodenal tumours in patients with familial adenomatous polyposis. Br J Surg 1996;83:225–8. - PubMed
    1. Penna C, Phillips R, Tiret E, et al. Surgical polypectomy of duodenal adenomas in familial adenomatous polyposis: an experience of two European centres. Br J Surg 1993;80:1027–9. - PubMed
    1. Penna C, Bataille N, Balladur, et al. Surgical treatment of severe duodenal polyposis in familial adenomatous polyposis. Br J Surg 1998;85:665–8 - PubMed

"VSports在线直播" Publication types

MeSH terms